Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 146, Issue 6, Pages 1427-1440
Publisher
Springer Science and Business Media LLC
Online
2020-05-17
DOI
10.1007/s00432-020-03186-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vanillic Acid Suppresses HIF-1α Expression via Inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK Pathways in Human Colon Cancer HCT116 Cells
- (2019) Jingli Gong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- “Vessels in the Storm”: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer
- (2018) Adriano Angelucci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The hypoxic tumour microenvironment
- (2018) Varvara Petrova et al. Oncogenesis
- Overview of advances in vasculogenic mimicry – a potential target for tumor therapy
- (2018) Hong Ge et al. Cancer Management and Research
- IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
- (2018) Giorgia Marisi et al. Cancer Management and Research
- Tumor-related interleukins: old validated targets for new anti-cancer drug development
- (2017) Sarra Setrerrahmane et al. Molecular Cancer
- IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
- (2017) Mariantonietta Di Salvatore et al. Oncotarget
- Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.
- (2017) C. Bernaards et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics
- (2016) Milena Krajnović et al. PATHOLOGY RESEARCH AND PRACTICE
- High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab
- (2016) Masayasu Hara et al. SURGERY TODAY
- Regulatory Roles of MAPK Phosphatases in Cancer
- (2016) Heng Boon Low et al. Immune Network
- BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis
- (2015) Wouter Willaert et al. BMC CANCER
- Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
- (2015) Patricia Alamo et al. FASEB JOURNAL
- Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer
- (2015) Wenbing Sun et al. OncoTargets and Therapy
- HIF-1α pathway: role, regulation and intervention for cancer therapy
- (2015) Georgina N. Masoud et al. Acta Pharmaceutica Sinica B
- RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases
- (2014) Yoshihiro Mise et al. ANNALS OF SURGICAL ONCOLOGY
- Differential gene expression of chemokines inKRASandBRAFmutated colorectal cell lines: Role of cytokines
- (2014) Sajjad Khan WORLD JOURNAL OF GASTROENTEROLOGY
- Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4
- (2014) Joseph M. Catanzaro et al. Nature Communications
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
- (2013) Jean-Nicolas Vauthey et al. ANNALS OF SURGERY
- The impact of KRAS mutations on VEGF-A production and tumour vascular network
- (2013) Agnès Figueras et al. BMC CANCER
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
- (2012) A Abajo et al. BRITISH JOURNAL OF CANCER
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer
- (2011) Noriaki Sunaga et al. INTERNATIONAL JOURNAL OF CANCER
- Clinicopathologic Significance of HIF-1α, CXCR4, and VEGF Expression in Colon Cancer
- (2010) Yugang Wu et al. Clinical & Developmental Immunology
- Hypoxia Activates the K-Ras Proto-Oncogene to Stimulate Angiogenesis and Inhibit Apoptosis in Colon Cancer Cells
- (2010) Min Zeng et al. PLoS One
- Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6
- (2010) YOSHIKO AOYAGI et al. Oncology Letters
- VEGF-A-stimulated signalling in endothelial cells via a dual receptor tyrosine kinase system is dependent on co-ordinated trafficking and proteolysis
- (2009) Alexander F. Bruns et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Oncogenic KRAS and BRAF Differentially Regulate Hypoxia-Inducible Factor-1 and -2 in Colon Cancer
- (2009) H. Kikuchi et al. CANCER RESEARCH
- K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRα in colorectal cancer
- (2009) Carl C. Schimanski et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats
- (2008) L LI et al. PHARMACOLOGICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More